Company Overview
Snapshot
Founded in July 2021, 1E Therapeutics operates with 11–50 employees. The company has raised $120 million across one funding round from Marius Nacht. In December 2021, the company secured a significant seed round.
Business overview
1E Therapeutics is a drug-development company specializing in RNA-targeting therapeutics. The company leverages a proprietary drug-design platform to create compounds addressing chronic life-threatening indications and emerging pathogens. Its pipeline includes lead compounds for oncology, age-related diseases, immunology, anti-microbial resistance, viral infections, and orphan neurological disorders, operating within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals.
Strategic signal
In December 2021, 1E Therapeutics raised a $120 million Seed round, just five months after its founding. This substantial early-stage funding indicates strong investor confidence in the company's proprietary RNA-targeting drug-design platform and its potential to develop novel therapeutics for a wide array of indications, signaling a rapid acceleration of its drug development efforts.
Log in to access full profile ›Company Intelligence Q&A
- What is 1E Therapeutics' primary focus?
- 1E Therapeutics is a drug-development company creating RNA-targeting therapeutics based on a proprietary drug-design platform.
- When was 1E Therapeutics founded?
- 1E Therapeutics was founded in July 2021.
- How much capital has 1E Therapeutics raised?
- 1E Therapeutics has raised a total of $120 million.
- What was a significant early funding event for 1E Therapeutics?
- In December 2021, 1E Therapeutics raised a $120 million Seed round, with Marius Nacht as a lead investor.
- What types of diseases does 1E Therapeutics aim to address?
- 1E Therapeutics has lead compounds addressing a wide array of indications in oncology, age-related diseases, immunology, anti-microbial resistance, viral infections, and orphan neurological disorders.